-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. On November 2, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” issued by the National Drug Administration (NMPA), and the marketing license application for oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist caverillone trometriol tablets (R&D code: HDM1002 tablets) for long-term adult weight control was accepted.

Zhitongcaijing·11/03/2026 12:25:19
Listen to the news
Zhitong Financial App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. On November 2, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” issued by the National Drug Administration (NMPA), and the marketing license application for oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist caverillone trometriol tablets (R&D code: HDM1002 tablets) for long-term adult weight control was accepted.